Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The HepConnect initiative aims to expand testing, harm reduction and health care infrastructure.
The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.
A look at the supply chain that results in very high costs for HIV and hepatitis C medications.
The subscription-based model is the first of its kind.
The placebo-controlled trial Phase III trial of selonsertib had sought to improve fibrosis while not worsening NASH.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.